Article ; Online: Purinergic Dysfunction in Pulmonary Arterial Hypertension.
Journal of the American Heart Association
2020 Volume 9, Issue 18, Page(s) e017404
Abstract: Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by increased pulmonary arterial pressure and pulmonary vascular resistance, which result in an increase in afterload imposed onto the right ventricle, leading to right ... ...
Abstract | Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by increased pulmonary arterial pressure and pulmonary vascular resistance, which result in an increase in afterload imposed onto the right ventricle, leading to right heart failure. Current therapies are incapable of reversing the disease progression. Thus, the identification of novel and potential therapeutic targets is urgently needed. An alteration of nucleotide- and nucleoside-activated purinergic signaling has been proposed as a potential contributor in the pathogenesis of PAH. Adenosine-mediated purinergic 1 receptor activation, particularly A |
---|---|
MeSH term(s) | Animals ; Humans ; Pulmonary Arterial Hypertension/metabolism ; Pulmonary Arterial Hypertension/physiopathology ; Purinergic Agents/pharmacology ; Receptors, Purinergic/drug effects ; Receptors, Purinergic/metabolism ; Receptors, Purinergic/physiology |
Chemical Substances | Purinergic Agents ; Receptors, Purinergic |
Language | English |
Publishing date | 2020-09-01 |
Publishing country | England |
Document type | Journal Article ; Research Support, Non-U.S. Gov't ; Review |
ZDB-ID | 2653953-6 |
ISSN | 2047-9980 ; 2047-9980 |
ISSN (online) | 2047-9980 |
ISSN | 2047-9980 |
DOI | 10.1161/JAHA.120.017404 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.